Scientists Create Pain Reliever Without Addiction Risk

Scientists just turned a deadly street drug into what could become the safest painkiller ever developed.

Researchers at the National Institutes of Health created DFNZ, a new medication derived from nitazenes, a class of synthetic opioids hundreds of times stronger than morphine. The experimental drug delivered powerful pain relief in lab tests without any of the terrifying side effects that make traditional opioids so dangerous.

"There's a lesson here that even a dangerous chemical can lead to a potential treatment," said Dr. Marc Siegel, Fox News senior medical analyst. The original nitazenes were abandoned in the 1950s because they were too addictive and deadly.

The breakthrough happened when researchers modified the drug's chemical structure. DFNZ worked within five to ten minutes and provided at least two hours of pain relief in mice. But here's what makes it revolutionary: it didn't slow breathing, cause addiction, or lead to tolerance even with repeated doses.

Traditional opioids kill by causing respiratory depression, where breathing becomes so slow that carbon dioxide builds up and oxygen levels plummet. DFNZ did the opposite. It actually increased oxygen flow to the brain rather than decreasing it.

The drug also releases dopamine more gradually than standard opioids, which scientists believe is key to preventing addiction. When researchers tested it repeatedly, they found no drug dependency and almost no withdrawal effects. The only symptom was mild irritability.

The Bright Side

This discovery could help millions of people suffering from cancer pain, chronic conditions, or recovering from surgery. Right now, patients face an impossible choice: live with agonizing pain or risk addiction and overdose with traditional opioids.

Dr. Nora Volkow, director of the National Institute on Drug Abuse, emphasized the stakes. "Developing a highly effective pain medication without these drawbacks would have enormous public health benefits," she said.

The medication might even help treat people already struggling with opioid addiction, offering a safer alternative during recovery.

The research team still needs to conduct more animal studies before seeking approval for human trials. Dr. Hooman Melamed, an orthopedic spine surgeon not involved in the study, called the findings "promising" but urged caution with early results.

Scientists say DFNZ has an unprecedented profile for an opioid, acting like both a powerful painkiller and a safer partial agonist. The findings appeared in the journal Nature.

A dangerous street drug just showed us the path to safer pain relief for everyone.